Drug Discovery - Medicine.net

Antimalarial drug candidate shows potential for fighting resistance and reducing malaria transmission

byWalter and Eliza Hall Institute of Medical ResearchThese images show the malaria parasites before and after treatment. Without MK-7602, parasites (purple) invade red blood cells (blue) after two day

Updated on: December 27,2025

Antimalarial drug candidate shows potential for fighting resistance and reducing malaria transmission

byWalter and Eliza Hall Institute of Medical ResearchThese images show the malaria parasites before and after treatment. Without MK-7602, parasites (purple) invade red blood cells (blue) after two day

Updated on:December 27,2025

Combined oral contraceptive use among people with migraine with aura persists, despite cautions

byBoston UniversityCredit: Pixabay/CC0 Public DomainCurrent medical guidelines discourage the use of combined oral contraceptives (COCs) among people who experience migraine with aura—a type of migrai

Updated on: December 27,2025

Combined oral contraceptive use among people with migraine with aura persists, despite cautions

byBoston UniversityCredit: Pixabay/CC0 Public DomainCurrent medical guidelines discourage the use of combined oral contraceptives (COCs) among people who experience migraine with aura—a type of migrai

Updated on:December 27,2025

$FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma$

FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma

by Lori SolomonThe U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatme

Updated on: December 27,2025

$FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma$

FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma

by Lori SolomonThe U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatme

Updated on:December 27,2025

FDA approves Waskyra for Wiskott-Aldrich syndrome

by Lori SolomonThe U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel) as the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).Waskyra is

Updated on: December 27,2025

FDA approves Waskyra for Wiskott-Aldrich syndrome

by Lori SolomonThe U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel) as the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS).Waskyra is

Updated on:December 27,2025